Business Wire

SMOORE

30.9.2021 14:23:06 CEST | Business Wire | Press release

Share
FEELM Reinforces its Commitment to Innovations in Atomization Technology at 2021 UK Media Day

SMOORE, a global leader in offering vaping technology solutions, today announced that its flagship atomization tech brand, FEELM, hosts 2021 UK Media Day at Silverstone Circuit. At the Media Day, Chief Scientist of SMOORE, Dr. Shi Zhiqiang, has reinforced FEELM’s commitment to innovations in atomization technology and affirmed that atomization coil is the key to the vape product performance and vaping experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005566/en/

As the flagship tech brand belonging to SMOORE, FEELM specializes in the development and manufacturing of high-quality closed pod vapes driven by its innovative FEELM coil.

FEELM coil technology features instant and high efficiency of atomization, smooth and pure taste until the last puff, smooth and delicate vapor, authentic flavor, and high nicotine delivery efficiency.

In 2019, FEELM launched the “FEELM Inside” global technology authentication trademark, as a symbol of excellent vaping experience for users. Today, the “FEELM inside” symbol is on the closed system pods of market-leading vaping brands around the world, such as RELX, NJOY, HAKA, HEXA, and VAPO.

“With the global launch of FEELM in 2016, FEELM has a significant impact on the research and manufacturing of closed vaping products, changing the global vaping industry landscape. The ‘FEELM inside’ symbol today is widely recognized by our partners and consumers as a certification of our commitment to quality, authenticity and high-quality vaping experience,” said Dr. Zhiqiang Shi, Chief Scientist of SMOORE. “Our Group has also made satisfying inroads in the research and development of medical and healthcare vaping products, with more than 1,000 scientists and experts from different backgrounds.”

Moreover, FEELM has adopted the industry’s first fully automated closed pod production line in 2019, realizing zero-staff inspection of product quality. To date, the productivity of a single line has reached a record high of 7,200 standard vaporizers per hour, and the annual production capacity of FEELM has surpassed three billion pieces.

Committed to SMOORE’s mission of “atomization making life better," FEELM has launched the world’s first taste evaluation model in December 2020. It covers four dimensions and 51 indexes, establishing a scientific system to evaluate vaping tastes. Moving forward, FEELM will also develop a Global Vape Flavor Map, by virtue of its global consumer base and extensive research on consumer behaviors.

As the world’s largest vaping device manufacturer in terms of revenue, SMOORE has accounted for 18.9% of the total global market share in 2020, according to Frost & Sullivan.

About FEELM:

FEELM is a flagship atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high-quality atomization devices driven by FEELM coil. The “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world.

About SMOORE:

SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release

EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu

NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release

Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,

TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release

Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac

Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release

HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of

Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release

Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye